Precigen (PGEN) Competitors $1.91 +0.11 (+6.11%) Closing price 04:00 PM EasternExtended Trading$1.94 +0.03 (+1.31%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PGEN vs. AGIO, IRON, DNLI, HRMY, IDYA, MESO, ADPT, ANIP, CGON, and VCELShould you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Agios Pharmaceuticals (AGIO), Disc Medicine (IRON), Denali Therapeutics (DNLI), Harmony Biosciences (HRMY), IDEAYA Biosciences (IDYA), Mesoblast (MESO), Adaptive Biotechnologies (ADPT), ANI Pharmaceuticals (ANIP), CG Oncology (CGON), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. Precigen vs. Its Competitors Agios Pharmaceuticals Disc Medicine Denali Therapeutics Harmony Biosciences IDEAYA Biosciences Mesoblast Adaptive Biotechnologies ANI Pharmaceuticals CG Oncology Vericel Precigen (NASDAQ:PGEN) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership. Do analysts rate PGEN or AGIO? Precigen presently has a consensus price target of $6.00, suggesting a potential upside of 214.14%. Agios Pharmaceuticals has a consensus price target of $56.33, suggesting a potential upside of 53.87%. Given Precigen's stronger consensus rating and higher possible upside, research analysts plainly believe Precigen is more favorable than Agios Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precigen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Agios Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is PGEN or AGIO more profitable? Agios Pharmaceuticals has a net margin of 1,590.42% compared to Precigen's net margin of -2,868.66%. Agios Pharmaceuticals' return on equity of -3.49% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Precigen-2,868.66% -340.89% -76.11% Agios Pharmaceuticals 1,590.42%-3.49%-3.23% Which has more volatility & risk, PGEN or AGIO? Precigen has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Do institutionals and insiders have more ownership in PGEN or AGIO? 33.5% of Precigen shares are held by institutional investors. 47.1% of Precigen shares are held by company insiders. Comparatively, 4.3% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has stronger valuation and earnings, PGEN or AGIO? Agios Pharmaceuticals has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecigen$3.92M143.82-$126.24M-$0.56-3.41Agios Pharmaceuticals$36.50M58.28$673.72M$11.003.33 Does the media refer more to PGEN or AGIO? In the previous week, Agios Pharmaceuticals had 1 more articles in the media than Precigen. MarketBeat recorded 7 mentions for Agios Pharmaceuticals and 6 mentions for Precigen. Agios Pharmaceuticals' average media sentiment score of 0.93 beat Precigen's score of 0.52 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAgios Pharmaceuticals beats Precigen on 10 of the 16 factors compared between the two stocks. Get Precigen News Delivered to You Automatically Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PGEN vs. The Competition Export to ExcelMetricPrecigenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$531.32M$3.04B$5.55B$9.83BDividend YieldN/A2.27%4.62%4.11%P/E Ratio-4.5520.6730.1526.03Price / Sales143.82367.61462.89105.43Price / CashN/A42.0537.7558.93Price / Book14.697.638.476.06Net Income-$126.24M-$54.65M$3.26B$265.11M7 Day Performance4.37%3.95%3.56%2.90%1 Month Performance4.37%11.46%5.97%3.99%1 Year Performance75.23%13.04%42.70%26.92% Precigen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PGENPrecigen4.0869 of 5 stars$1.91+6.1%$6.00+214.1%+68.2%$531.32M$3.92M-4.55190News CoverageEarnings ReportAnalyst ForecastAGIOAgios Pharmaceuticals4.3354 of 5 stars$35.10-1.8%$56.33+60.5%-20.9%$2.04B$40.88M3.19390Insider TradeIRONDisc Medicine3.2244 of 5 stars$58.59+1.0%$95.73+63.4%+31.1%$2.03BN/A-13.1130Earnings ReportDNLIDenali Therapeutics4.2077 of 5 stars$13.91-0.3%$33.85+143.3%-41.3%$2.02B$330.53M-5.21430News CoverageEarnings ReportGap UpHRMYHarmony Biosciences4.6834 of 5 stars$34.80+1.8%$51.00+46.6%+6.2%$2.00B$714.73M11.23200Analyst RevisionIDYAIDEAYA Biosciences4.1835 of 5 stars$22.84-1.1%$48.09+110.6%-37.2%$2.00B$7M-6.0380Analyst RevisionMESOMesoblast1.5353 of 5 stars$14.70-2.2%$18.00+22.4%+133.1%$1.88B$5.90M0.0080Positive NewsADPTAdaptive Biotechnologies2.8712 of 5 stars$12.15-0.4%$12.38+1.9%+194.4%$1.85B$178.96M-14.82790ANIPANI Pharmaceuticals3.7826 of 5 stars$84.88+4.2%$84.75-0.2%+48.0%$1.84B$674.07M-110.23600Earnings ReportAnalyst ForecastHigh Trading VolumeCGONCG Oncology1.9163 of 5 stars$23.94-3.7%$55.30+131.0%-24.2%$1.82B$1.14M-13.5361Earnings ReportUpcoming EarningsAnalyst RevisionVCELVericel2.3616 of 5 stars$35.43-2.2%$60.33+70.3%-19.6%$1.79B$249.12M295.27300Positive News Related Companies and Tools Related Companies AGIO Competitors IRON Competitors DNLI Competitors HRMY Competitors IDYA Competitors MESO Competitors ADPT Competitors ANIP Competitors CGON Competitors VCEL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PGEN) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access